Focused On-demand Library for Anaphase-promoting complex subunit 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UJX3

UPID:

APC7_HUMAN

Alternative names:

Cyclosome subunit 7

Alternative UPACC:

Q9UJX3; Q96AC4; Q96GF4; Q9BU24; Q9NT16

Background:

Anaphase-promoting complex subunit 7 (APC7) is a pivotal component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is instrumental in controlling mitosis and the G1 phase of the cell cycle, primarily through the mediation of 'Lys-11'-linked polyubiquitin chains. Although not essential for APC/C assembly, APC7 enhances the complex's specificity by facilitating the ubiquitination of particular substrates, including the clearance of MKI67 from constitutive heterochromatin, which is crucial for brain development.

Therapeutic significance:

APC7's involvement in Ferguson-Bonni neurodevelopmental syndrome, a disorder marked by developmental delays and intellectual impairment, underscores its potential as a therapeutic target. Understanding the role of APC7 could open doors to potential therapeutic strategies for treating this syndrome and possibly other neurodevelopmental disorders.